Inosine pranobex

Identification

Name
Inosine pranobex
Accession Number
DB13156
Description

Inosine pranobex (Isoprinosine or Methisoprinol) is a combination of inosine, acetamidobenzoic acid, and dimethylaminoisopropanol used as an antiviral drug.

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 1115.249
Monoisotopic: 1114.554641092
Chemical Formula
C52H78N10O17
Synonyms
  • IAD
  • Inosine acedobene dimepranol
  • Inosine pranobex
  • Inosine-2-hydroxypropyldimethylammonium 4-acetamidobenzoate (1:3)
  • Inosiplex
  • Isoprinosine
  • Methisoprinol
External IDs
  • NP-113
  • NPT-10381

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication

Inosine pranobex is also indicated for mucocutaneous infections due to herpes simplex virus (type 1 and type II) and for treatment of genital warts as adjunctive therapy to podophyllin or carbon dioxide laser.

Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Works by slowing the growth and spread of the virus in the body. It may also stimulate the immune system in the body, which helps to increase the body's ability to fight these infections.

Mechanism of action

Inosine pranobex stimulates cell-mediated immune processes to viral infections.

Absorption

Rapidly absorbed from GIT

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination

Via urine

Half-life

50 min

Clearance
Not Available
Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Mouse LD50 (Intravenous ): 1570 mg/kg Mouse LD50 (Oral) : 9410mg/kg Mouse LD50 (subcutaneous) ; 2960mg/kg

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirAbacavir may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
AceclofenacAceclofenac may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
AcetaminophenAcetaminophen may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
AcetazolamideAcetazolamide may increase the excretion rate of Inosine pranobex which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
AclidiniumAclidinium may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
AcrivastineAcrivastine may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
AcyclovirAcyclovir may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
Adefovir dipivoxilAdefovir dipivoxil may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
No interactions found.

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
ImunovirTabletOralKora Healthcare2000-01-25Not applicableCanada flag
IsoprinosineTabletOralNewport Pharmaceuticals International1997-06-052000-02-04Canada flag
Isoprinosine Tab 500mgTabletOralNewport Pharms International Inc.1983-12-311996-09-10Canada flag
Isoprinosine Tab 500mgTabletOralSystemed Inc.1993-12-311996-09-10Canada flag

Categories

ATC Codes
J05AX05 — Inosine pranobex
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as purine nucleosides. These are compounds comprising a purine base attached to a ribosyl or deoxyribosyl moiety.
Kingdom
Organic compounds
Super Class
Nucleosides, nucleotides, and analogues
Class
Purine nucleosides
Sub Class
Not Available
Direct Parent
Purine nucleosides
Alternative Parents
Glycosylamines / 6-oxopurines / Pentoses / Hypoxanthines / Benzoic acids / Benzoyl derivatives / Pyrimidones / N-substituted imidazoles / Vinylogous amides / Tetrahydrofurans
show 14 more
Substituents
1,2-aminoalcohol / 6-oxopurine / Alcohol / Amine / Aromatic heteropolycyclic compound / Azacycle / Azole / Benzenoid / Benzoic acid / Benzoic acid or derivatives
show 38 more
Molecular Framework
Not Available
External Descriptors
Not Available

Chemical Identifiers

UNII
W1SO0V223F
CAS number
36703-88-5
InChI Key
YLDCUKJMEKGGFI-KSIULYHRSA-N
InChI
InChI=1S/C10H12N4O5.3C9H9NO3.3C5H13NO/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18;3*1-6(11)10-8-4-2-7(3-5-8)9(12)13;3*1-5(7)4-6(2)3/h2-4,6-7,10,15-17H,1H2,(H,11,12,18);3*2-5H,1H3,(H,10,11)(H,12,13);3*5,7H,4H2,1-3H3/t4-,6-,7-,10-;;;;3*5-/m1...111/s1
IUPAC Name
tris((2R)-1-(dimethylamino)propan-2-ol); tris(4-acetamidobenzoic acid); 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-1H-purin-6-one
SMILES
C[C@@H](O)CN(C)C.C[C@@H](O)CN(C)C.C[C@@H](O)CN(C)C.CC(=O)NC1=CC=C(C=C1)C(O)=O.CC(=O)NC1=CC=C(C=C1)C(O)=O.CC(=O)NC1=CC=C(C=C1)C(O)=O.OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1N=CNC2=O

References

General References
  1. ChemIDplus [Link]
  2. Pubchem [Link]
KEGG Drug
D01995
PubChem Compound
131704326
PubChem Substance
347829266
ChemSpider
58829622
RxNav
6048
Wikipedia
Inosine_pranobex
AHFS Codes
  • 08:18.00 — Antivirals
  • 08:18.92 — Miscellaneous Antivirals

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
3Not Yet RecruitingPreventionCoronavirus Disease 2019 (COVID‑19)1
3Not Yet RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19) / Respiratory Tract Infections (RTI)1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections3
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Lymphatic Diseases3

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SyrupOral
TabletOral
Capsule
CreamTopical
GranuleOral
Granule, for solutionOral
InjectionIntramuscular; Intravenous
InsertVaginal
TabletOral500 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility13.8 mg/mLALOGPS
logP-1.9ALOGPS
logP-2.5ChemAxon
logS-1.3ALOGPS
pKa (Strongest Acidic)8.93ChemAxon
pKa (Strongest Basic)0.58ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area129.2 Å2ChemAxon
Rotatable Bond Count14ChemAxon
Refractivity61.33 m3·mol-1ChemAxon
Polarizability24.6 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on December 04, 2016 00:28 / Updated on April 11, 2021 00:58